Dr. Shelby Sullivan watched as 45 patients at her New Hampshire clinic struggled to maintain a 15 percent loss in body weight. These patients had utilized tirzepatide, the active ingredient in blockbuster drugs like Zepbound, but many are now facing the risk of weight regain. The crisis is compounded by a new FDA proposal that would block pharmacies from making cheaper, compounded versions of these GLP-1 medications.

Eli Lilly and Novo Nordisk shares surged following the announcement. The two firms dominate a market on track to drive U.S. prescription spending past $1 trillion this year. While Eli Lilly CEO Dave Ricks announced that 20,000 people are already taking the new Foundayo pill, the medication remains gated by cost and insurance coverage.

"Ozempic breath" has become a common side effect as the drugs slow digestion, forcing users to buy gum and mints to mask the scent of fermenting food. Users are told to consume high protein diets of chicken, fish, and Greek yogurt to prevent muscle loss. However, for many working-class patients, these dietary requirements are as unaffordable as the $1,000-a-month retail price of the injections.

This move by the FDA ensures that the metabolic health of the nation remains a corporate subscription. By removing generic alternatives, the state has actively enforced a metabolic divide. Only those with premium insurance or high cash reserves can afford to stay thin in an age of engineered obesity.